GlassScriptPhysician profile
Ritu Sood
NPI 1780883900
$4,309.49
in general payments reported to CMS, 2019-2025
33 companies · $292 in 2025
The $292 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $665 · 2021: $909 · 2022: $1,360 · 2023: $448 · 2024: $284 · 2025: $292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,024.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,023.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $636.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $526.85 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $466.19 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $400.45 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Abbvie INC. | $380.16 | 2019-2025 | Vraylar |
| Glaxosmithkline, LLC. | $275.48 | 2021-2025 | Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.45 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $167.73 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $158.86 | 2019-2022 | |
| Horizon Therapeutics Plc | $150.43 | 2020 | |
| Pfizer INC. | $112.50 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $90.03 | 2020-2021 | |
| Daiichi Sankyo INC. | $84.15 | 2023-2024 | Injectafer |
| Abbott Laboratories | $74.91 | 2022-2024 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $60.80 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $60.02 | 2020-2025 | Licart, Tirosint, Flector |
| Merck Sharp & Dohme LLC | $57.58 | 2021-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| E.R. Squibb & Sons, L.L.C. | $41.93 | 2022 | |
| Corcept Therapeutics | $36.94 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $35.36 | 2021 | |
| Idorsia Pharmaceuticals US INC | $34.36 | 2022-2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $30.87 | 2020-2022 | |
| Esperion Therapeutics, INC. | $30.29 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.87 | 2022 | |
| Incyte Corporation | $25.80 | 2022 | |
| Exact Sciences Corporation | $25.33 | 2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $24.83 | 2024 | Aptima |
| Dexcom, INC. | $22.35 | 2023 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $22.00 | 2025 | Auvelity |
| Edwards Lifesciences Corporation | $19.39 | 2023 | Sapien 3 Ultra Resilia |
| Astellas Pharma US INC | $18.37 | 2023 | Veozah |
| Otsuka America Pharmaceutical, INC. | $18.10 | 2023 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.33 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ritu Sood listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.